Burney Co. Cuts Stock Position in ACADIA Pharmaceuticals Inc. $ACAD

Posted by George Bondi on Jul 9th, 2026

Burney Co. cut its stake in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) by 43.1% in the 1st quarter, Holdings Channel.com reports. The firm owned 59,970 shares of the biopharmaceutical company’s stock after selling 45,441 shares during the period. Burney Co.’s holdings in ACADIA Pharmaceuticals were worth $1,335,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently bought and sold shares of the company. State Street Corp lifted its stake in shares of ACADIA Pharmaceuticals by 9.0% in the 4th quarter. State Street Corp now owns 7,910,733 shares of the biopharmaceutical company’s stock worth $211,296,000 after acquiring an additional 655,257 shares during the period. Geode Capital Management LLC lifted its position in ACADIA Pharmaceuticals by 3.4% in the fourth quarter. Geode Capital Management LLC now owns 3,239,451 shares of the biopharmaceutical company’s stock valued at $86,539,000 after purchasing an additional 106,807 shares during the period. Dimensional Fund Advisors LP boosted its holdings in ACADIA Pharmaceuticals by 4.4% in the 4th quarter. Dimensional Fund Advisors LP now owns 2,920,974 shares of the biopharmaceutical company’s stock valued at $78,019,000 after purchasing an additional 122,840 shares in the last quarter. Braidwell LP purchased a new stake in ACADIA Pharmaceuticals in the 3rd quarter valued at approximately $50,760,000. Finally, Marshall Wace LLP increased its position in ACADIA Pharmaceuticals by 19.8% during the 3rd quarter. Marshall Wace LLP now owns 2,358,881 shares of the biopharmaceutical company’s stock worth $50,339,000 after purchasing an additional 389,170 shares during the period. 96.71% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, insider James Kihara sold 5,401 shares of the firm’s stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $21.18, for a total value of $114,393.18. Following the completion of the transaction, the insider owned 24,509 shares in the company, valued at $519,100.62. This trade represents a 18.06% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Mark C. Schneyer sold 3,506 shares of ACADIA Pharmaceuticals stock in a transaction on Monday, May 4th. The stock was sold at an average price of $21.79, for a total value of $76,395.74. Following the transaction, the executive vice president directly owned 66,145 shares of the company’s stock, valued at $1,441,299.55. This trade represents a 5.03% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 10,239 shares of company stock valued at $219,813. Company insiders own 26.20% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the company. Bank of America increased their target price on ACADIA Pharmaceuticals from $29.00 to $30.00 and gave the stock a “buy” rating in a research note on Tuesday, June 30th. Royal Bank Of Canada upped their price objective on ACADIA Pharmaceuticals from $29.00 to $36.00 and gave the stock an “outperform” rating in a report on Tuesday. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and issued a $37.00 price objective on shares of ACADIA Pharmaceuticals in a research report on Monday, June 29th. Citigroup raised their target price on ACADIA Pharmaceuticals from $32.00 to $35.00 and gave the company a “buy” rating in a report on Monday, June 29th. Finally, Weiss Ratings lowered shares of ACADIA Pharmaceuticals from a “hold (c+)” rating to a “hold (c)” rating in a research report on Friday, May 1st. Twelve research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, ACADIA Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $32.94.

View Our Latest Report on ACAD

ACADIA Pharmaceuticals Price Performance

ACAD opened at $26.00 on Thursday. ACADIA Pharmaceuticals Inc. has a 1-year low of $19.69 and a 1-year high of $28.35. The stock has a market cap of $4.45 billion, a P/E ratio of 11.82, a P/E/G ratio of 18.87 and a beta of 0.80. The stock’s 50 day simple moving average is $22.42 and its 200 day simple moving average is $23.38.

ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report) last issued its quarterly earnings data on Wednesday, May 6th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($0.02). The firm had revenue of $268.10 million for the quarter, compared to analyst estimates of $280.25 million. ACADIA Pharmaceuticals had a return on equity of 9.61% and a net margin of 34.30%.The business’s revenue for the quarter was up 9.7% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.11 earnings per share. Research analysts expect that ACADIA Pharmaceuticals Inc. will post 0.37 EPS for the current fiscal year.

ACADIA Pharmaceuticals Profile

(Free Report)

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company’s flagship product, NUPLAZID® (pimavanserin), received U.S.